Telehealth has moved far beyond its early role as a stopgap solution during moments of disruption. Today, it is becoming a foundational part of modern healthcare delivery. Providers, payers, technology platforms, and patients are all adapting to a world where digital access is no longer optional. Instead, it is expected.
As healthcare systems continue to
Regulatory activity in the EU and UK over the past month has focused on AI in health care, health data access, and digital innovation frameworks. Recent regulatory developments in the EU and UK point to a decisive shift from high level policy ambition to the practical mechanics of enabling AI driven health care, with particular
The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.
On 21 May 2026, the MHRA launched its consultation on the Proposed Framework, representing a significant step in the UK’s ambition to become a global leader in the development
Zhu v Lee; Zhu v Mordecai; Zhu v Mordecai [2026] NSWSC 532 (Link to Caselaw).
This relevance of this matter is clearly limited by its facts, however is of interest as an example of orders which may be made where proceedings have been commenced by a person who was found to be not capable
The headlines are provocative: “AI Outperforms Doctors in Diagnosing Breast Cancer,” “Machine Learning Algorithm Predicts Heart Disease Better Than Cardiologists.” It’s natural to wonder if artificial intelligence is poised to replace physicians. But that’s not what the technology is actually doing—and it’s not what will happen. Instead, we’re witnessing something more nuanced and powerful: the
Irani v ACT [2026] ACTSC 168 (Link to JADE).
Ms Iravani gave birth to her second child in 2022 at the Canberra Hospital. She claimed that the medical services she received as they related to the birth did not meet the requisite standard of care and caused her injury, including psychological injury.
In preparing
Regulatory activity in the EU and UK over the past month has focused on accelerating the alignment of digital, AI, and life sciences regulatory frameworks, alongside increasing scrutiny of data governance and market readiness for emerging technologies. At the EU level, work to simplify and streamline EU AI-related legislation has advanced, with the Council of
Health Ombudsman v Rathie [2026] QCAT 180 (Link to AUSTLII).
Ren Li drew attention to this unusual conduct matter, though it is interesting to consider whether some of the patients might have pursued breach of privacy claims.
Dr R had published 6 books, culminating in the book which is the subject of this note: The
As procurement fraud enforcement continues to be a priority for the Department of Justice and other federal agencies, we take a look back at significant 2025 enforcement developments affecting government contractors, grant recipients and participants in federal programs in our 2025 Procurement Fraud Review.
The secondary market has grown to roughly $220 billion as GPs and LPs scramble for liquidity in a private markets cycle stuck in a “worse distribution profile” for three and a half years. Chris Lawrence, managing partner at Labyrinth Capital Partners, joins McGuireWoods partner and host Geoff Cockrell to demystify GP-led secondaries.
Chris
